Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX

Tanios S. Bekaii-Saab

Subscribe

Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX

Interview with the Innovators

Pancreatic Cancer Patient Education

Videos

Tanios S. Bekaii-Saab, MD

David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ

Shubham Pant, MD

Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX

Michael Pishvaian, MD, PhD

Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this ninth installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations for using NALIRIFOX or FOLFIRINOX when treating patients with pancreatic cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Deciding Between Triplet Therapy for the Treatment of Pancreatic Cancer: NALIRIFOX and FOLFIRINOX

Related Items

Sponsored By

Subscribe Today!

I'd like to receive:

We Value Your Feedback! Tell Us How You Consume Content